India using Kashmir to oppose Silk Road project: Chinese media

executive@coastaldigest.com (Agencies)
March 30, 2017

Beijing, Mar 30: India sees China's Silk Road initiative as a geopolitical competition and is using the Kashmir issue as an "unfounded excuse" to oppose the ambitious project, Chinese state media today alleged and asked New Delhi to "abandon" its "cliche mentality".

"The official reason the Indian government rejected the offer to join the initiative (Silk Road) is that it is designed to pass through Kashmir. However, it is just an unfounded excuse as Beijing has been maintaining a consistent position on the Kashmir issue, which has never changed," one of the two articles on India by state-run Global Times said.

China1"India sees the Belt and Road initiative as a geopolitical competition," the article said, criticising India for hindering Beijing's push into South Asia and the world with multi-billion Silk Road project which is also known as the 'Belt and Road' (BR).

"Whether to continue to boycott or join the Belt and Road remains a conundrum for New Delhi," it said adding that, India is the only one which can help itself. The article said that India should give up its "biased" view on the BR initiative. "It is high time to abandon the cliche mentality of associating everything with geopolitics.

India will surely see a different world if it does," the article said. Referring to India's reservations to attend the BR summit called by Chinese President Xi Jinping, the article said it may be an "embarrassing occasion" for India as the meeting is backed by "China's peripheral countries, notably Russia, Indonesia, Kazakhstan and Pakistan".

Chinese Foreign Minister Wang Yi recently said 20 heads of state will attend the summit, together with over 50 leaders from international organisations, over 100 ministerial officials and more than 1,200 guests from around the world.

The article referred to a comment by Foreign Secretary S Jaishankar during his visit here last month to co-chair the upgraded India-China strategic dialogue, saying India is examining China's invitation to attend the summit and "how a country whose sovereignty has been violated can come on aninvitation".

In the meantime, however, state-run Chinese media stepped up campaign to pressurise India to join the summit. China apparently is keen about India's participation in the summit as the project struggled to make headway in the region except the USD 46 billion China Pakistan Economic Corridor (CPEC) where both Beijing-Islamabad are putting all efforts to show early harvest.

Media reports here said that Xi plans to invite his US counterpart Donald Trump to attend the meeting during their first summit early next month in Florida. BR consisted of maze of roads, including CPEC, Bangladesh-China-India-Myanmar Economic (BCIM) Corridor and 21st Maritime Silk Road besides road network to connect China with Eurasia.

The article also said, "it seems that the mainstream opinion throughout India is that the connectivity brought about by BR initiative is geopolitically significant. Therefore, India cannot allow the initiative to expand further into South Asia".

"This could also explain why the BCIM has seen no progress since its proposed by Chinese Premier Li Keqiang in 2013, and also why New Delhi has been keen on Japan's investment in the Iranian port of Chabahar," it said.

"New Delhi may also feel embarrassed as Moscow has actively responded to the Belt and Road initiative and will build an economic corridor with China and Mongolia," it said, adding Russia and Iran seeking to join the CPEC putting "India in a more awkward position".

It said, "Beijing has expressed, on various occasions, its anticipation to see New Delhi join the grand project and to make concerted effort with India in building economic corridors involving China, India, Sri Lanka, Nepal, Bangladesh and Myanmar".

Another article in the same daily said a "benign" competition between India and China may help development in South Asia but they should avoid "cut-throat" rivalry. "The so-called dragon-elephant contention is perhaps a blow against strategic mutual trust between Beijing and New Delhi, but may be conducive to development in South Asia," it said.

Accusing India of not being "generous" to its neighbours, it said "a yawning infrastructure funding gap in South Asian countries creates space for China and those nations to strengthen economic cooperation".

"Bangladesh and China signed 27 deals worth billions of dollars during President Xi Jinping's visit last year," it said, adding China's BR initiative has received an increasing amount of attention from Bangladesh.

"Only by investing more resources in regional integration and extending the benefits from India's rapid economic growth to other South Asian countries can New Delhi maintain its influence in the region," it said.

"Benign competition between China and India will be conducive to development in South Asia. The question remaining is how to avoid cut-throat competition as Beijing and New Delhi jostle for influence. India and China should seek common ground while strengthening cooperation with South Asian countries to promote regional integration," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 25,2020

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Y UDAYA CHANDAR
 - 
Monday, 13 Apr 2020

Dear Sir,

 

I am 77 but a very healthy person with remarkable immunity. I contracted Malaria fever in 1994 because of mosquito biting and I have not been sick anytime there after, not even for ordinary fever in the last 26 years.

 

I am sure you would like to conduct the trials on persons of varying criteria. I am sure you don't want to carry out the trials on perfectly healthy young individuals only. 

 

I am certain that  you want to try the vaccine on a 'common man' from 'general public.' I am ready for the trial and you can take me. I will be delighted. 

 

If you are not handling this matter kindly forward this mail to the correct agency.

 

I look forward to hearing from you.

 

Best regards.

 

If you are not moving forward, you are really moving backward.

Y Udaya Chandar

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 14,2020

San Francisco, Mar 14: Microsoft on friday announced that co-founder Bill Gates has left its board of directors to devote more time to philanthropy.

The 64-year-old stopped being involved in day-to-day operations at the firm more than a decade ago, turning his attention to the foundation he launched with his wife, Melinda.

Gates served as chairman of Microsoft's board of directors until early in 2014 and has now stepped away entirely, according to the Redmond-based technology giant.

“It's been a tremendous honor and privilege to have worked with and learned from Bill over the years,” Microsoft chief executive and company veteran Satya Nadella said in a release.

Nadella said Microsoft would continue to benefit from Gates' “technical passion and advice” in his continuing role as a technical advisor.
“I am grateful for Bill's friendship and look forward to continuing to work alongside him,” he added.

Gates left his CEO position in 2000, handing the company reins to Steve Ballmer to devote more time to his charitable foundation.

He gave up the role of chairman at the same time Nadella became Microsoft's third CEO in 2014.

Regularly listed among the world's richest people, William H. Gates was a geeky-looking young man when he and Paul Allen co-founded Microsoft in 1975.

Gates went on to turn his attention from software to fighting disease and other humanitarian challenges with his wife, under the auspices of the Bill and Melinda Gates Foundation.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 4,2020

Geneva, Jul 4: The World Health Organization has updated its account of the early stages of the COVID crisis to say it was alerted by its own office in China, and not by China itself, to the first pneumonia cases in Wuhan.

The UN health body has been accused by US President Donald Trump of failing to provide the information needed to stem the pandemic and of being complacent towards Beijing, charges it denies.

On April 9, WHO published an initial timeline of its communications, partly in response to criticism of its early response to the outbreak that has now claimed more than 521,000 lives worldwide.

In that chronology, WHO had said only that the Wuhan municipal health commission in the province of Hubei had on December 31 reported cases of pneumonia. The UN health agency did not however specify who had notified it.

WHO director Tedros Adhanom Ghebreyesus told a press conference on April 20 the first report had come from China, without specifying whether the report had been sent by Chinese authorities or another source.

But a new chronology, published this week by the Geneva-based institution, offers a more detailed version of events.

It indicates that it was the WHO office in China that on December 31 notified its regional point of contact of a case of "viral pneumonia" after having found a declaration for the media on a Wuhan health commission website on the issue.

The same day, WHO's epidemic information service picked up another news report transmitted by the international epidemiological surveillance network ProMed -- based in the United States -- about the same group of cases of pneumonia from unknown causes in Wuhan.

After which, WHO asked the Chinese authorities on two occasions, on January 1 and January 2, for information about these cases, which they provided on January 3.

WHO emergencies director Michael Ryan told a press conference on Friday that countries have 24-48 hours to officially verify an event and provide the agency with additional information about the nature or cause of an event.

Ryan added that the Chinese authorities immediately contacted WHO's as soon as the agency asked to verify the report.

US President Donald Trump has announced that his country, the main financial contributor to WHO, will cut its bridges with the institution, which he accuses of being too close to China and of having poorly managed the pandemic.

The WHO denies any complacency toward China.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.